Cancer trial prescreening is one of the biggest bottlenecks between a cancer diagnosis and access to a potentially life changing study. FOMAT has partnered with Massive Bio to close that gap, combining Massive Bio’s AI driven patient matching technology with FOMAT’s embedded research infrastructure to give oncology patients a faster, more direct path from prescreening to enrollment.
The Problem Cancer Trial Prescreening Is Meant to Solve
For many cancer patients, the hardest part of finding a clinical trial is not eligibility itself, it is discovery. Patients often do not know a relevant study exists, and physicians do not always have the time or tools to screen every patient against active trial criteria. Cancer trial prescreening typically happens too late, after other treatment options have already been exhausted. This partnership is built to move that screening earlier in the patient journey, when trial participation can have the most impact and the most benefit.
How the Partnership Works
Massive Bio’s platform uses AI to prescreen cancer patients against active clinical trial criteria at scale, identifying likely candidates before they ever speak with a research team. FOMAT then connects those prescreened patients to the physician practices and clinical sites where FOMAT’s embedded infrastructure already operates. Because FOMAT builds research capacity directly inside existing physician practices rather than running a separate network of independent sites, patients are referred into care settings that are already familiar to them, reducing hesitation and delay.
3 Proven Benefits of Better Cancer Trial Prescreening
1. Faster access for patients. If you or a family member has been told you may be eligible for a cancer clinical trial, this partnership is designed to shorten the distance between that moment and actual enrollment. Cancer trial prescreening, done well, means less time spent searching, fewer dead ends, and a clearer sense of which studies are actually a fit. Patients identified through Massive Bio’s prescreening process will have a more direct path to FOMAT affiliated physicians and sites participating in relevant oncology studies.
2. A model built on trusted physician relationships. FOMAT operates as an Embedded Research Organization, or ERO. That means clinical trial infrastructure, including staff, workflows, and regulatory support, is built directly inside existing physician practices instead of operating as a standalone site network. This model matters for cancer trial prescreening because it keeps research close to where patients already receive care. When a patient is prescreened and referred through this partnership, they are being connected to a physician relationship that already exists, not sent to an unfamiliar, separate facility.
3. Stronger enrollment quality for sponsors and CROs. For sponsors and CROs running oncology studies, upstream prescreening quality has a direct effect on downstream enrollment metrics. Better cancer trial prescreening means fewer screen fails, stronger protocol fit, and referrals that arrive already aligned with study criteria. Paired with FOMAT’s embedded site model, this partnership is designed to support more efficient, community connected enrollment specifically for cancer trials, an area where recruitment timelines are often tightest and every day matters.
A Powerful Step Forward for Cancer Research Access
This partnership reflects a broader, powerful shift in how cancer trial prescreening is being built, pairing AI powered matching with research infrastructure that already lives inside the physician practices patients trust. Rather than treating prescreening and enrollment as two separate systems, this collaboration brings them closer together, so patients spend less time navigating and more time getting answers.
FOMAT will continue expanding these kinds of partnerships to make cancer trial prescreening faster, more accurate, and more connected to real world care. As oncology trials become more complex and competitive, this kind of upstream collaboration between prescreening technology and embedded research infrastructure is likely to become the standard rather than the exception.
Read the full announcement on BusinessWire.